University of Kansas Medical Center Enhances Robotic Heart Care Program with Genesis Robotic Technology
Stereotaxis (NYSE: STXS) announced that the University of Kansas Health System has successfully implemented and treated its first patients using the Genesis Robotic Magnetic Navigation (RMN) System. The Genesis System represents the latest advancement in robotic technology for cardiac ablation procedures, treating arrhythmias with robotic precision and safety. Dr. Seth Sheldon, Cardiac Electrophysiologist at the facility, highlighted how the system's precision and stability enable delivery of personalized treatments, improving patient outcomes and quality of life. The technology has been used to treat over 150,000 patients globally.
Stereotaxis (NYSE: STXS) ha annunciato che il Sistema Sanitario dell'Università del Kansas ha implementato con successo e trattato i suoi primi pazienti utilizzando il Genesis Robotic Magnetic Navigation (RMN) System. Il Sistema Genesis rappresenta l'ultimo avanzamento nella tecnologia robotica per le procedure di ablazione cardiaca, trattando le aritmie con precisione e sicurezza robotica. Il Dr. Seth Sheldon, elettrofisiologo cardiaco della struttura, ha evidenziato come la precisione e la stabilità del sistema consentano di fornire trattamenti personalizzati, migliorando i risultati per i pazienti e la qualità della vita. La tecnologia è stata utilizzata per trattare oltre 150.000 pazienti a livello globale.
Stereotaxis (NYSE: STXS) anunció que el Sistema de Salud de la Universidad de Kansas ha implementado y tratado con éxito a sus primeros pacientes utilizando el Genesis Robotic Magnetic Navigation (RMN) System. El Sistema Genesis representa el último avance en tecnología robótica para procedimientos de ablación cardiaca, tratando arritmias con precisión y seguridad robótica. El Dr. Seth Sheldon, electrofisiólogo cardiaco en la instalación, destacó cómo la precisión y estabilidad del sistema permiten ofrecer tratamientos personalizados, mejorando los resultados de los pacientes y su calidad de vida. La tecnología se ha utilizado para tratar a más de 150,000 pacientes a nivel mundial.
스테레오택시스 (NYSE: STXS)는 캔자스 대학교 병원이 제네시스 로봇 자력 내비게이션(RMN) 시스템을 사용하여 첫 번째 환자를 성공적으로 치료했다고 발표했습니다. 제네시스 시스템은 심장 절제술을 위한 로봇 기술의 최신 발전을 나타내며, 로봇의 정확성과 안전성으로 부정맥을 치료합니다. 시설의 심장 전기생리학자인 세스 셀던 박사는 시스템의 정확성과 안정성이 개인 맞춤형 치료의 제공을 가능하게 하여 환자 결과와 삶의 질을 향상시키는 방법을 강조했습니다. 이 기술은 전 세계적으로 150,000명 이상의 환자를 치료하는 데 사용되었습니다.
Stereotaxis (NYSE: STXS) a annoncé que le Système de Santé de l'Université du Kansas a réussi à mettre en œuvre et à traiter ses premiers patients utilisant le Genesis Robotic Magnetic Navigation (RMN) System. Le système Genesis représente la dernière avancée dans la technologie robotique pour les procédures d'ablation cardiaque, traitant les arythmies avec précision et sécurité robotique. Le Dr Seth Sheldon, électrophysiologiste cardiaque de l'établissement, a souligné comment la précision et la stabilité du système permettent d'offrir des traitements personnalisés, améliorant ainsi les résultats pour les patients et leur qualité de vie. La technologie a été utilisée pour traiter plus de 150 000 patients dans le monde entier.
Stereotaxis (NYSE: STXS) gab bekannt, dass das University of Kansas Health System erfolgreich sein erstes Patienten behandelt hat, indem es das Genesis Robotic Magnetic Navigation (RMN) System eingesetzt hat. Das Genesis-System stellt den neuesten Fortschritt in der Robotiktechnologie für herzchirurgische Ablationsverfahren dar und behandelt Arrhythmien mit robotischer Präzision und Sicherheit. Dr. Seth Sheldon, kardiologischer Elektrophysiologe der Einrichtung, hob hervor, wie die Präzision und Stabilität des Systems die Bereitstellung maßgeschneiderter Behandlungen ermöglichen und die Patientenergebnisse sowie die Lebensqualität verbessern. Die Technologie wurde weltweit zur Behandlung von über 150.000 Patienten eingesetzt.
- Successful implementation of Genesis RMN System at major health facility
- Technology has been used in treatment of over 150,000 patients globally
- Expansion of market presence through partnership with prominent healthcare provider
- None.
Insights
The installation of the Genesis RMN System at the University of Kansas Health System represents an incremental business development rather than a significant revenue catalyst for Stereotaxis. While system installations contribute to market presence, this single deployment is unlikely to materially impact the company's
The Genesis platform's technological advantages in cardiac ablation procedures could support long-term growth through recurring revenue from procedures and disposable components. However, the lengthy sales cycles for capital equipment in healthcare and significant competition in the electrophysiology market temper immediate financial expectations.
Market penetration in major healthcare systems is positive for brand recognition but must be weighed against the substantial costs of commercialization and system deployment. Investors should monitor procedure volumes and adoption rates as key metrics for evaluating the commercial success of these installations.
ST. LOUIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the University of Kansas Health System have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.
The health system is renowned for diagnosing and treating complex heart conditions. The Genesis System is the latest advancement in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
“For years, advanced robot technology has been instrumental in our ability to deliver superior care to our patients, allowing us to navigate complex cardiac procedures with improved accuracy and safety,” said Dr. Seth Sheldon, Cardiac Electrophysiologist at the health system. “The robotic precision and stability offered by the Genesis System allows us to deliver precise, personalized treatments to our patients, ultimately improving outcomes and quality of life.”
“We are proud to continue our partnership with the health system to deliver exceptional cardiac care to patients in Kansas City,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to continuing to support their successful and impactful robotic heart rhythm care program.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What is the Genesis Robotic System announced by Stereotaxis (STXS)?
How many patients have been treated with Stereotaxis (STXS) technology globally?
Which healthcare facility recently implemented Stereotaxis (STXS) Genesis System?
